|
| Pneumonia on initial CXR 11 total patients (as a % of pneumonia patients) | No Pneumonia on initial CXR 13 total patients (as a % of patients without pneumonia) |
| Most common symptoms prior to stroke |
|
|
| Fever | 4 (36.4%) | 1 (7.7%) |
| Cough | 4 (36.4%) | 1 (7.7%) |
| Dyspnea | 2 (18.2%) | 1 (7.7%) |
| No prior symptoms suggesting infection (asymptomatic COVID-19) | 1 (9.1%) | 6 (46.2%) |
| Treated with COVID-19 targeted therapy | 10 (90.9%) | 7 (53.8%) |
| Chest X-Ray | ||
| Abnormal CXR on admission - had either infiltrations or consolidations | 11 (100%) | 0 |
| New pneumonia developed during admission - admitted with normal CXR | 0 | 8 (61.5%) |
| Laboratory Findings | ||
| Elevated white blood cells (WBCs) | 2 (18.2%) | 2 (15.4%) |
| Elevated PCT | 7 (63.6%) | 7 (53.8%) |
| Elevated CRP | 7 (63.6%) | 4 (30.8%) |
| High platelet count | 1 (9.1%) | 0 |
| Low platelet count | 0 | 2 (15.4%) |
| Elevated ferritin | 3 (27.3%) | 3 (23.1%) |
| Elevated D-dimer | 6 (54.5%) | 8 (61.5%) |
| Elevated prothrombin time (PT) | 11 (100%) | 12 (92.3%) |
| Elevated activated partial thromboplastin time (APTT) | 1 (9.1%) | 1 (7.7%) |
| International normalized ratio (INR) | 3 (27.3%) | 4 (30.8%) |